A first Quebec patient implanted with Victhom Neurostep(TM) at Hôpital de l'Enfant-Jésus of CHA

    The Neurostep(TM) is a novel neuromodulator aimed at treating people with
    foot drop syndrome secondary to stroke.

    QUEBEC CITY, July 8 /CNW Telbec/ - Victhom Human Bionics, "Victhom" (TSX:
VHB) and the Centre hospitalier affilié universitaire de Québec (CHA) are
happy to announce the implantation of Victhom neuromodulator, the
Neurostep(TM), in a first Quebec patient during a surgical intervention
performed last June 27 at Hôpital de l'Enfant-Jésus. Other patients from the
institution will also be implanted with this medical device developed by
Victhom and aimed at treating gait disorders (including "foot drop") that may
result from a central nervous system lesion caused by conditions such as
    "We are very happy that our innovative technology can now directly
benefit patients from Quebec City, where Victhom was founded, and this with
the support of a major hospital in the region and its outstanding medical
staff. The Neurostep(TM) is the first neuromodulator capable of both
collecting sensory signals from nerves and stimulating the appropriate muscle
group to lift the foot in synchronization with the patient's gait. This is
what we call our unique Closed-Loop neuromodulation System (CLS)", stated
Victhom's acting President and CFO, Mr. Normand Rivard.
    "The neurosurgery department and Hôpital de l'Enfant-Jésus are proud to
be associated with Victhom, a Quebec company, in this study for the
development of a new type of smart neuromodulator aimed at treating some
neurological dysfunctions caused by a brain or spinal cord injury. This
innovation will allow people with partial paralysis of the foot and reduced
walking ability to restore their mobility more easily and safely. This study
still further demonstrates the strength of Quebec companies in the field of
neurological science and biomedical engineering, and the motivation to
constantly surpass themselves to help patients in their difficulties and
health problems", added Dr. Michel Prud'Homme, neurosurgeon and director of
neurosurgery research at CHA.
    The surgical intervention at Hôpital de l'Enfant-Jésus of CHA was
performed by Dr. Jean-François Turcotte, neurosurgeon at CHA. "The operation
went very well. The patient is recovering nicely from the operation and will
soon be able to familiarize himself with the Neurostep(TM). For people with
foot drop, the Neurostep(TM) offers new hope to improve their quality of life,
allowing a more comfortable gait with reduced effort and energy expenditure.
We are very happy to participate in the clinical trial of the Neurostep(TM)
and thus contribute to the advance of treatments for people with foot drop, a
condition that affects a large number of people in Canada and other parts of
the world", he concluded.
    The surgical interventions to be performed in Quebec City are within the
framework of a multicenter clinical trial of the Neurostep(TM) initiated by
Victhom to test the safety and efficacy of the medical device. The preliminary
results of this clinical trial last spring turned out promising with regards
to the capacity of the Neurostep(TM) to collect sensory signals and generate
the appropriate nervous stimulation. Trials to come will also serve to measure
the clinical benefits of the neuromodulator for the patient, like to increase
walking speed and distance walked.

    About Victhom

    Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics ("O&P") market.

    About Centre hospitalier affilié universitaire de Québec (CHA)

    Comprised of Hôpital de l'Enfant-Jésus and Hôpital du Saint-Sacrement,
the Centre hospitalier affilié universitaire de Québec provides the community
of the Capitale Nationale region and Eastern part of the Province of Quebec
with general, specialized and ultraspecialized care, notably in neurological
science. Affiliated to Université Laval, CHA is devoted to care, education and
research. Through its academic mission, it is also a member of the Integrated
Health University Network (RUIS) of Université Laval. CHA has 644 health care
beds in both hospitals, with complementary vocations. These vocations are,
moreover, supported by over 4 500 employees including 560 physicians,
pharmacists and dentists in 14 departments and 35 clinical units. For more
information about CHA, see the following Web site: www.cha.quebec.qc.ca

    (*) Forward-looking statements contained in this press release involve
    known and unknown risks, uncertainties or other factors that may cause
    actual results, performance or achievements of the Company to be
    materially different from any future results, performance or achievements
    expressed or implied by such forward-looking statements.

For further information:

For further information: Normand Rivard, Acting President and Chief
Financial Officer, Victhom Human Bionics, (418) 872-5665,
normand.rivard@victhom.com; Media Relations: Frédéric Tremblay, HKDP
Communications and Public Affairs, (514) 395-0375, ext. 234,
ftremblay@hkdp.qc.ca; Geneviève Dupuis, Assistant to the Executive Director
and Communications Manager, Centre hospitalier affilié universitaire de Québec
(CHA), (418) 649-5587, genevieve.dupuis.cha@ssss.gouv.qc.ca; Sources: Victhom
Human Bionics Inc.; Centre hospitalier affilié universitaire de Québec (CHA)

Organization Profile

Victhom Human Bionics Inc.

More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890